Versiporosin's Unique IPF Treatment Progresses with Positive Phase 2 Safety Data
Daewoong's Versiporosin shows safety in Phase 2 for IPF; final evaluation by 2025.
Breaking News
Jul 29, 2024
Mrudula Kulkarni

Versiforocin's unique mode of action, which directly
inhibits collagen formation, is likely to set it apart from standard therapies
in terms of safety and efficacy. The 24-week clinical trial assesses the
efficaciousness, safety, and tolerability of both verciporocin monotherapy and
combination therapy with established therapies. Since the trials' launch in
January 2023 in the United States and South Korea, 61 patients have been
recruited, which represents around 60% of the 102 individuals that were
originally intended.